<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123811</url>
  </required_header>
  <id_info>
    <org_study_id>GC-CIF-2005</org_study_id>
    <nct_id>NCT01123811</nct_id>
  </id_info>
  <brief_title>Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer</brief_title>
  <acronym>GC-CIF-2005</acronym>
  <official_title>An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the current promising results with irinotecan and cetuximab in patients with&#xD;
      recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in&#xD;
      gastric cancer , the present clinical study to evaluate the overall response rate, the time&#xD;
      to progression and the overall survival of the combined treatment of cetuximab and irinotecan&#xD;
      and 5-FU in patients with esophagogastric cancer is urgently needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab will be analysed with biological markers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Adenocarcinoma of Stomach or Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Cetuximab IF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with combination of Cetuximab and Irinotecan 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab IF</intervention_name>
    <description>Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36</description>
    <arm_group_label>Cetuximab IF</arm_group_label>
    <other_name>na-folinat oncofolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Signed and dated informed consent before the start of specific protocol procedures;&#xD;
&#xD;
          -  Histologically proven gastric adenocarcinoma including adenocarcinoma of the&#xD;
             esophagogastric junction or Barrett carcinoma (adenocarcinoma of lower oesophagus);&#xD;
&#xD;
          -  Measurable metastatic disease according to the RECIST criteria. If locally recurrent&#xD;
             disease, it must be associated with at least one measurable lymph node (&gt; 20 mm by CT&#xD;
             scan or &gt; 10 mm with spiral CT);&#xD;
&#xD;
          -  Age: 18-75 years;&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks;&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal functions: ANC&#xD;
&#xD;
             ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L; hemoglobin ≥ 10g/dl; creatinine ≤ 2 x UNL;&#xD;
             total bilirubin ≤ 3 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 3 × UNL; in case of liver&#xD;
             metastases: total bilirubin ≤ 5 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 5 × UNL;&#xD;
&#xD;
          -  At least 4 weeks from surgery;&#xD;
&#xD;
          -  Recovery from side effects of any prior therapy;&#xD;
&#xD;
          -  Able to comply with scheduled assessments and with management of toxicity.&#xD;
&#xD;
          -  If of childbearing potential, willingness to use effective contraceptive method for&#xD;
             the study duration and 2 months post-dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumor type than adenocarcinoma (e.g., leiomyosarcoma, lymphoma) or a second&#xD;
             cancer except in patients with squamous or basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix which has been effectively treated. Patients&#xD;
             curatively treated and disease free for at least 5 years will be discussed with the&#xD;
             sponsor before inclusion;&#xD;
&#xD;
               -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
                  indicated in the study protocol;&#xD;
&#xD;
               -  Any prior palliative chemotherapy, adjuvant (and/or neoadjuvant) chemotherapy or&#xD;
                  radiotherapy ;&#xD;
&#xD;
               -  Concurrent treatment with any other anti-cancer therapy;&#xD;
&#xD;
               -  Patients with known brain or leptomeningeal metastasis;&#xD;
&#xD;
               -  Hypercalcemia not controlled by bisphosphonates;&#xD;
&#xD;
               -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive&#xD;
                  intestinal resection (&gt; hemicolectomy or extensive small intestine resection with&#xD;
                  chronic diarrhea), Crohn's disease, ulcerative colitis;&#xD;
&#xD;
               -  Other serious illness or medical conditions:&#xD;
&#xD;
          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
             prior to study entry; congestive heart failure NYHA grade 3 and 4;&#xD;
&#xD;
          -  Current history of chronic diarrhea;&#xD;
&#xD;
          -  History of significant neurologic or psychiatric disorders including dementia or&#xD;
             seizures;&#xD;
&#xD;
          -  Active uncontrolled infection;&#xD;
&#xD;
          -  Active disseminated intravascular coagulation;&#xD;
&#xD;
          -  Other serious underlying medical conditions which could impair the ability of the&#xD;
             patient to participate in the study;&#xD;
&#xD;
               -  Known deficit in DPD&#xD;
&#xD;
               -  Contraindications to the use of atropine;&#xD;
&#xD;
               -  Concomitant or within a 4-week period administration of any other experimental&#xD;
                  drug under investigation;&#xD;
&#xD;
               -  Pregnant or lactating women;&#xD;
&#xD;
               -  Previous exposure to monoclonal antibodies, signal transduction inhibitors or&#xD;
                  EGFR pathway targeting therapy;&#xD;
&#xD;
               -  Known allergic/hypersensitivity reaction to any of the components of the&#xD;
                  treatment;&#xD;
&#xD;
               -  Known drug abuse/alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Moehler, Md Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg Univetsity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Städtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg, Medizinische Klinik I</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-Württemberg</state>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Abt. Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der technischen Universität München, III. Medizinische Klinik: Hämatologie / Onkologie</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abteilung Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Essen, Innere Klinik und Poliklinik - Tumorforschung</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte / Evang. Huyssens-Stiftung, Klinik für Innere Medizin I und Internistische Onkologie / Hämatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital Recklinghausen, Medizinische Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg-Universität, I. Medizinische Klinik u. Poliklinik</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Benjamin Franklin, Medizinische Klinik I</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>May 12, 2010</last_update_submitted>
  <last_update_submitted_qc>May 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>M Moehler</name_title>
    <organization>Johannes Gutenberg University Mainz</organization>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>esophagogastric junction cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

